Cargando…
Major depressive disorder: Validated treatments and future challenges
Depression is a prevalent psychiatric disorder that often leads to poor quality of life and impaired functioning. Treatment during the acute phase of a major depressive episode aims to help the patient reach a remission state and eventually return to their baseline level of functioning. Pharmacother...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610877/ https://www.ncbi.nlm.nih.gov/pubmed/34877271 http://dx.doi.org/10.12998/wjcc.v9.i31.9350 |
_version_ | 1784603181978746880 |
---|---|
author | Karrouri, Rabie Hammani, Zakaria Benjelloun, Roukaya Otheman, Yassine |
author_facet | Karrouri, Rabie Hammani, Zakaria Benjelloun, Roukaya Otheman, Yassine |
author_sort | Karrouri, Rabie |
collection | PubMed |
description | Depression is a prevalent psychiatric disorder that often leads to poor quality of life and impaired functioning. Treatment during the acute phase of a major depressive episode aims to help the patient reach a remission state and eventually return to their baseline level of functioning. Pharmacotherapy, especially selective serotonin reuptake inhibitors antidepressants, remains the most frequent option for treating depression during the acute phase, while other promising pharmacological options are still competing for the attention of practitioners. Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses. Electroconvulsive therapy is the most effective somatic therapy for depression in some specific situations; meanwhile, other methods have limits, and their specific indications are still being studied. Combining medications, psychotherapy, and somatic therapies remains the most effective way to manage resistant forms of depression. |
format | Online Article Text |
id | pubmed-8610877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-86108772021-12-06 Major depressive disorder: Validated treatments and future challenges Karrouri, Rabie Hammani, Zakaria Benjelloun, Roukaya Otheman, Yassine World J Clin Cases Review Depression is a prevalent psychiatric disorder that often leads to poor quality of life and impaired functioning. Treatment during the acute phase of a major depressive episode aims to help the patient reach a remission state and eventually return to their baseline level of functioning. Pharmacotherapy, especially selective serotonin reuptake inhibitors antidepressants, remains the most frequent option for treating depression during the acute phase, while other promising pharmacological options are still competing for the attention of practitioners. Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses. Electroconvulsive therapy is the most effective somatic therapy for depression in some specific situations; meanwhile, other methods have limits, and their specific indications are still being studied. Combining medications, psychotherapy, and somatic therapies remains the most effective way to manage resistant forms of depression. Baishideng Publishing Group Inc 2021-11-06 2021-11-06 /pmc/articles/PMC8610877/ /pubmed/34877271 http://dx.doi.org/10.12998/wjcc.v9.i31.9350 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Review Karrouri, Rabie Hammani, Zakaria Benjelloun, Roukaya Otheman, Yassine Major depressive disorder: Validated treatments and future challenges |
title | Major depressive disorder: Validated treatments and future challenges |
title_full | Major depressive disorder: Validated treatments and future challenges |
title_fullStr | Major depressive disorder: Validated treatments and future challenges |
title_full_unstemmed | Major depressive disorder: Validated treatments and future challenges |
title_short | Major depressive disorder: Validated treatments and future challenges |
title_sort | major depressive disorder: validated treatments and future challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610877/ https://www.ncbi.nlm.nih.gov/pubmed/34877271 http://dx.doi.org/10.12998/wjcc.v9.i31.9350 |
work_keys_str_mv | AT karrourirabie majordepressivedisordervalidatedtreatmentsandfuturechallenges AT hammanizakaria majordepressivedisordervalidatedtreatmentsandfuturechallenges AT benjellounroukaya majordepressivedisordervalidatedtreatmentsandfuturechallenges AT othemanyassine majordepressivedisordervalidatedtreatmentsandfuturechallenges |